Clinical observation of estrogen supplementation combined with Dexzopi-clone in the treatment of perimenopausal sleep disorders
Objective To observe the clinical value of estrogen supplementation combined with Dexzopiclone in the treat-ment of perimenopausal sleep disorders.Methods A total of 82 patients with perimenopausal sleep disorders diagnosed in Xinyu People's Hospital from September 2020 to September 2022 were selected and devided in the control group(39 cases)and the observation group(43 cases)according to the patients'own selection.The control group was treated with Estradiol/Estradiol and Dydrogesterone Tablets,and the observation group was treated with Dexzopicolone on the basis of the control group.Before and after treatment,the scores of Pittsburgh sleep quality index(PSQI)and self-rating scale of sleep(SRSS)were observed,the liver function,blood lipid and fasting blood glucose levels of the patients were compared,and the inci-dence of adverse reactions of the two groups was recorded.Results The PSQI and SRSS scores of the observation group were lower than those of the control group 15 days and 1 and 3 months after treatment,and the differences were statistically sig-nificant(P＜0.05).There were no significant differences in total bilirubin(TBiL),total cholesterol(TC)and fasting blood glucose between the two groups after treatment(P＞0.05).TBiL level after treatment in both groups were higher than those before the treatment,and the differences were statistically significant(P＜0.05).There was no statistically significant differ-ence in the total incidence of adverse reactions between the two groups during treatment(P＞0.05).Conclusion Dexzopi-clone combined with estrogen is more effective than single estrogen treatment,and it is more effective and safe for patients with perimenopausal sleep disorders,which is worthy of clinical combined drug treatment.
万方数据
维普
